Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)
QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.
Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.
The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.
Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.
This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.
Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ipsen Clinical Study Enquiries
- Phone Number: See email
- Email: clinical.trials@ipsen.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.
Description
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
- Males ≥18 years old.
- Patient with histologically confirmed PCa.
- Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
- Patient able to understand and complete study-related questionnaires.
- Patient having been informed and not opposed to participating in the study.
- Patient covered by healthcare insurance.
Exclusion Criteria
Patients will not be included in the study if they meet any of the following criteria:
- Patient currently participating in any interventional clinical trial.
- Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
- Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Time Frame: At 6 months
|
At 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants' baseline demographic characteristics
Time Frame: At baseline
|
Including:
|
At baseline
|
|
Participants' clinical characteristics at baseline
Time Frame: At baseline
|
Including:
|
At baseline
|
|
Prostate cancer characteristics at diagnosis and baseline
Time Frame: At baseline
|
Including:
|
At baseline
|
|
Participants symptoms at baseline
Time Frame: At baseline
|
At baseline
|
|
|
Participants' PCa treatment patterns at baseline
Time Frame: At baseline
|
|
At baseline
|
|
Participants' healthcare pathway/supportive care done or planned
Time Frame: At baseline
|
Including:
|
At baseline
|
|
Evolution of PCa at 6-month follow-up according to investigator's opinion
Time Frame: At 6 months
|
Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression. |
At 6 months
|
|
Symptoms and biological characteristics at 6 months
Time Frame: At 6 months
|
At 6 months
|
|
|
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
Time Frame: At 6 months
|
The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity. |
At 6 months
|
|
Participants' Quality Of life (QoL)
Time Frame: At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' PCa treatment patterns at 6 months
Time Frame: At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' healthcare pathway/supportive care at 6 months
Time Frame: At 6 months
|
• Participant's healthcare pathway/type of supportive care in case of changes. |
At 6 months
|
|
Identification of factors associated with participant's quality of life
Time Frame: At 6 months
|
• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model. |
At 6 months
|
|
Percentage of participants with adverse events
Time Frame: From enrollment to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up. |
From enrollment to Month 6
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Ipsen Medical Director, Ipsen
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CLIN-52014-030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD Sharing Time Frame
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD Sharing Access Criteria
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.